Multi-Cancer Early Detection

How It Works

Tumors shed DNA fragments into the bloodstream. MCED tests use machine learning to detect methylation patterns characteristic of cancer—and to predict which tissue the cancer originated from. A single blood draw can theoretically screen for dozens of cancer types, including pancreatic, ovarian, and other cancers with poor prognosis and no standard screening.

Sensitivity varies dramatically by cancer stage and type. Late-stage cancers are detected more reliably than early-stage ones—which is precisely the opposite of what screening needs to be most useful.

Why It Matters for Luxury

MCED tests are being adopted fastest in the luxury health market, where patients pay out-of-pocket and demand cutting-edge technology. This creates a natural experiment: will early adopters demonstrate benefits that justify broader use, or will they absorb the costs of a technology that wasn't ready for deployment? The willingness of wealthy patients to serve as early adopters—and bear the risks of uncertainty—is itself a distinctive feature of luxury medicine.